AbbVie (NYSE:ABBV) announces a quarterly dividend of $1.07



AbbVie (NYSE:ABBV) to go ex-dividend.
On 2/21/2019 AbbVie ( NYSE:ABBV ) announced that it will be issuing a quarterly dividend in the amount of $1.07 down from $1.07


AbbVie (NYSE:ABBV) Ex- dividend date

AbbVie (NYSE:ABBV) is set to go ex-dividend on and will be payable on 5/15/2019


Dividend History for AbbVie (NYSE:ABBV)
The next payable dividend for AbbVie is scheduled for 5/15/2019. There is an annual dividend of $$4.28 with a yield of 5.45% The company’s dividend has increased by 21.10% on a 3 Year Average

Recent Dividend History for AbbVie (NYSE:ABBV)

  • On 1/4/2013 AbbVie announced a quarterly dividend of $0.40.
  • On 1/7/2013 AbbVie announced a special dividend of $0.40.
  • On 2/15/2013 AbbVie announced a quarterly dividend of $0.40.
  • On 6/20/2013 AbbVie announced a quarterly dividend of $0.40.
  • On 9/19/2013 AbbVie announced a quarterly dividend of $0.40.
  • On 12/12/2013 AbbVie announced a quarterly dividend of $0.40.
Story continues below



About Company
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid for hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers. AbbVie Inc. has collaborations with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer – Commercialization of Research; the Université de Montréal; Tolero Pharmaceuticals, Inc.; Galapagos; Mission Therapeutics Ltd; Bristol-Myers Squibb Company; Voluntis; and Tizona Therapeutics, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Recent Insider Trading for AbbVie (NYSE:ABBV)

  • On 12/28/2018 Laura J Schumacher, Vice Chairman, sold 25,000 with an average share price of $90.00 per share and the total transaction amounting to $2,250,000.00.
  • On 12/28/2018 Laura J Schumacher, Vice Chairman, sold 25,000 with an average share price of $90.00 per share and the total transaction amounting to $2,250,000.00.
  • On 12/12/2018 William J Chase, EVP, sold 60,000 with an average share price of $90.00 per share and the total transaction amounting to $5,400,000.00.
  • On 12/11/2018 Richard A Gonzalez, Chairman, sold 16,850 with an average share price of $88.75 per share and the total transaction amounting to $1,495,437.50.
  • On 12/4/2018 Laura J Schumacher, Insider, sold 94,140 with an average share price of $93.58 per share and the total transaction amounting to $8,809,621.20.
  • On 11/29/2018 Henry O Gosebruch, EVP, sold 42,450 with an average share price of $90.10 per share and the total transaction amounting to $3,824,745.00.



Recent Analyst Rating for AbbVie (NYSE:ABBV)

  • On 2/14/2019 Barclays, Reiterated Rating, to Hold with a price target of $86.00
  • On 1/25/2019 Credit Suisse Group, Set Price Target, to Hold with a price target of $79.00
  • On 1/23/2019 UBS Group, Reiterated Rating, fromNeutral to Neutral with a price target of $97.00 to $91.00
  • On 1/3/2019 Bank of America, Downgrade, fromBuy to Neutral
  • On 12/26/2018 Standpoint Research, Initiated Coverage, fromBuy to Buy
  • On 12/20/2018 Morgan Stanley, Set Price Target, to Hold with a price target of $88.00



Recent Trading for AbbVie (NYSE:ABBV)
Shares of AbbVie closed the previous trading session at with 3946972 shares trading hands.

An ad to help with our costs